Category Archives: Genetics

Singapore Precision Medicine Program to Analyze Genetics of 150K Citizens – GenomeWeb

NEW YORK Singapore's National Precision Medicine (NPM) program has kicked off a four-year research initiative to analyze the genetics of 150,000 of its citizens, organizations involved in the effort announced on Wednesday.

The NPM program was launched in 2017 with a 10-year timeline to help establish the frameworks and infrastructure to roll out precision medicine throughout the country. The first phase of the effort focused on building a genetic databank for multi-ethnic Asian populations, which was completed in late 2019 with data on 10,000 healthy Singaporeans.

Continue reading here:
Singapore Precision Medicine Program to Analyze Genetics of 150K Citizens - GenomeWeb

Genetic testing: Everything you need to know – The Indian Express

As per the Organization of Rare diseases in India (ORDI), 1 in 20 Indians is affected by a rare disorder. More than 7,000 rare diseases are known and reported worldwide; from these approximately 80 per cent are known to have a genetic predisposition. Some of these common rare diseases weve heard of are inherited cancers (eg. breast, ovarian, and colorectal etc.), hemoglobinopathies (hemophilia, thalassemia, and sickle cell anemia etc.), auto-immune deficiencies, and lysosomal storage disorders among others, says Dr Aparna Dhar, head of department: medical genetics and genetic counselling, CRE Diagnostics.

In the year 2020, the world has undergone massive changes. It has made us introspect and re-evaluate our lives. Weve started looking after our wellbeing by addressing issues associated with mental health and physical health. Weve consciously tried to bring about lifestyle changes that have been coupled with teaming up with healthcare/diagnostic providers to give us a more personalised approach. One key way of doing this is by understanding if they have a genetic pre-disposition to a hereditary disorder, she adds.

A global study conducted by the Mayo Clinic, USA stated that 1 in 10 people who underwent predictive genetic testing, learned that they had a hereditary risk for a health condition and could actually benefit from preventive care. While no genetic test can accurately predict the exact date and time a disease may present, it will definitely be able to tell if an individual is at a higher risk vs the general population risk.

However, Dr Dhar says that there is definitely a lack of awareness around these genetic disorders, misconception about genetic diseases and testing, taboo talking about a potential familial disorder, and cost challenges.

Below, she addresses some of these:

What is a genetic test?

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder. More than 1,000 genetic tests are currently in use, and more are being developed. Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue.

For example, a procedure called a buccal smear uses a small brush or cotton swab to collect a sample of cells from the inside surface of the cheek. The sample is sent to a laboratory where technicians look for specific changes in chromosomes, DNA, or proteins, depending on the suspected disorder. The laboratory reports the test results in writing to a persons doctor or genetic counselor, or directly to the patient if requested.

How should one prepare for genetic testing?

Genetic testing can provide important, life-saving information. Interpreting the results is critical. It can be difficult for a medical doctor to understand the result if they dont have specialized training in genetics. Thats why genetic counselors exist. They are trained in both medical genetics and counseling and work closely with your doctor to provide both clinical and emotional advice. They are available to guide, to make sure if you are a good fit for the test and help interpret results. Whereas for some, they might have second thoughts and might not recommend genetic testing as it is not for everyone. While there is perceived stigma of resulting to some disease or bad gene still lies, a counselor will help you understand what the results mean for you and your family.

What useful information can genetic testing provide?

*Genetic testing can provide clarity on the results, guide therapy selection and monitoring, and allow disease risk profiling*Family health history tells you which diseases run in your family*Identify risks due to shared genes*Understand better what lifestyle and environmental factors you share with your family*Understand how healthy lifestyle choices can reduce your risk of developing a disease

The results of genetic tests are not always straightforward, which often makes them challenging to interpret and explain. Therefore, it is important for patients and their families to ask questions about the potential meaning of genetic test results both before and after the test is performed. When interpreting test results, healthcare professionals consider a persons medical history, family history, and the type of genetic test that was done.

A positive test result means that the laboratory found a change in a particular gene, chromosome, or protein of interest. Depending on the purpose of the test, this result may confirm a diagnosis, indicating that a person is a carrier of a particular genetic mutation, identify an increased risk of developing a disease (such as cancer) in the future or suggest a need for further testing. Because family members have some genetic material in common, a positive test result may also have implications for certain blood relatives of the person undergoing testing. It is important to note that a positive result of a predictive or pre-symptomatic genetic test usually cannot establish the exact risk of developing a disorder. Also, health professionals typically cannot use a positive test result to predict the course or severity of a condition.

A negative test result means that the laboratory did not find a change in the gene, chromosome, or protein under consideration. This result can indicate that a person is not affected by a particular disorder, is not a carrier of a specific genetic mutation, or does not have an increased risk of developing a certain disease. It is possible, however, that the test missed a disease-causing genetic alteration because many tests cannot detect all genetic changes that can cause a particular disorder. Further testing may be required to confirm a negative result.

In some cases, a test result might not give any useful information. This type of result is called uninformative, indeterminate, inconclusive, or ambiguous. Uninformative test results sometimes occur because everyone has common, natural variations in their DNA, called polymorphisms that do not affect health. If a genetic test finds a change in DNA that has not been associated with a disorder in other people, it can be difficult to tell whether it is a natural polymorphism or a disease-causing mutation. An uninformative result cannot confirm or rule out a specific diagnosis, and it cannot indicate whether a person has an increased risk of developing a disorder. In some cases, testing other affected and unaffected family members can help clarify this type of result.

Path to well-being

Genetic testing is not limited to only helping from a preventive and proactive perspective, but for those affected with disease; there is a shift to personalised medicine paradigm of disease modeling and targeted gene therapy which has yielded excellent results. In addition, the data from the Human Genome Project has helped us understand the stratification of genes as per their penetrance levels and in turn, help us give a personalised risk assessment to our patients.

Excerpt from:
Genetic testing: Everything you need to know - The Indian Express

Medical schools need to prepare doctors for revolutionary advances in genetics – The Conversation CA

Human diversity did not appear to matter to modern medicine. At the time, the state of medical practice ignored the differences between individuals and between men and women.

This practice was reflected in how doctors were trained. They took courses in basic biology, biochemistry, anatomy and physiology. But genetics, the science of variation, was not a required course until recently.

Advances in genetics research have slowly transformed the practice of medicine. There has been a slow accumulation of a long list of diseases caused by variations in a single gene. Since the disease-causing variants generally occurred with some exception in low frequency, these diseases did not occupy the mainstream concern of the medical profession.

All this changed with the Human Genome Project (HGP). Completed in 2003, the sequencing of human genome pushed us into a new era of how genetic diseases would be defined, and how future health services would be delivered.

Medical schools need to do a lot better preparing future physicians and health professionals if the dreams of personalized medicine are to be realized.

Personalized medicine means treating patients based on the individual characteristics of their DNA. The information can be used either in direct intervention, as in cancer treatment, or in predictive medicine.

Different specializations would require varying levels of proficiency: for example, family physicians would need a sufficient background in genetics, while oncologists would need in-depth education.

The HGP made two big promises. First, it promised personalized predictive medicine based on an individuals genome sequences. Disease-causing mutations at different locations on a gene would be identified, and an overall personalized risk score would be calculated that would tell the individual his or her chances of developing that disease.

The second promise was to develop a better and faster cures for complex diseases such as cancer.

The letdown came when genomic studies showed that genes affecting complex diseases were potentially large in number and individually of small effect, and worse still, only a small number of all potential genes affecting a given disease could be identified.

Even more problematic, it turned out that all individuals sharing the same risk factor for a given disease did not develop the disease. This creates a problem for predictive medicine if scientists cannot link a disease to a gene with any certainty.

The uncovered genomic complexity of diseases was contrary to expectations of the Mendelian model, which did not account for genetic variations beyond one gene one disease.

This is where the work my collaborators and I carried out in our labs comes in. Our work in population genetics and evolutionary genomics relates to how these characteristics are calculated and combined into an overall score used in predictive medicine.

My lab specializes in the evolution of molecular complexity and its impact on precision medicine. We also study variation and evolution of sex and reproduction related genes and their role in the evolution of sexual dimorphism in complex diseases and mental disorders. We reviewed three decades of relevant work in genetics, genomics and molecular evolution and drew the following conclusions.

First, we showed that because of the blind nature of evolutionary forces and the role of chance in evolution in humans, many combinations of genes can lead to the same disease. This implies the existence of a considerable amount of redundancy in the molecular machinery of the organism.

Second, we showed that genes do not work alone: gene-gene and gene-environment interactions are a major part of any organisms functional biology. This would explain, for example, why some women with breast cancer genes develop breast or ovarian cancer and some do not.

Third, we showed that since males fight for mates and early reproduction, this would lead to an evolution of male-benefitting mutations even at the cost of them being harmful later, making males vulnerable to diseases in their old age. Male-benefitting mutations harmful to females would trigger a female-driven response leading to the evolution of increased female immunity, and possibly evolution of higher thresholds for complex diseases and mental disorders.

This would explain why many diseases such as autism are more common in boys than girls. In addition, some differences in disease prevalence, such as depression in women, is theorized to be the result of interaction between hormone fluctuation and social stress factors.

If you have sought medical attention, its likely that your doctor may have asked you about your parents and your siblings. Your physician is interested in knowing if there are any health conditions, such as cardiovascular disease, diabetes or high blood pressure that run in the family and that might affect your health.

Future physicians will need to know a lot more than their patients family history.

The number of situations that involve relevant genetic contributions will continue to increase with advances in molecular insights and precision medication. The medical research establishment is becoming increasingly aware of the importance of individual genetic differences and of sex and gender when assessing diseases and health-care proposals. Health professionals must have sufficient expertise in diversity, genomics and gene-environment (gene-drug) interaction.

Future physicians will be part of health networks involving medical lab technicians, data analysts, disease specialists and the patients and their family members. The physician would need to be knowledgeable about the basic principles of genetics, genomics and evolution to be able to take part in the chain of communication, information sharing and decision-making process.

This would require a more in-depth knowledge of genomics than generally provided in basic genetics courses.

Much has changed in genetics since the discovery of DNA, but much less has changed how genetics and evolution are taught in medical schools.

In 2013-14 a survey of course curriculums in American and Canadian medical schools showed that while most medical schools taught genetics, most respondents felt the amount of time spent was insufficient preparation for clinical practice as it did not provide them with sufficient knowledge base. The survey showed that only 15 per cent of schools covered evolutionary genetics in their programs.

A simple viable solution may require that all medical applicants entering medical schools have completed rigorous courses in genetics and genomics.

Link:
Medical schools need to prepare doctors for revolutionary advances in genetics - The Conversation CA

In memoriam: Louis Siminovitch, the father of genetic research in Canada – News@UofT

The University of Toronto community is remembering University ProfessorLouis Siminovitch,a scientific visionary who was the first chair of what is today the department ofmolecular geneticsin the Temerty Faculty of Medicine.

Siminovitch, who was alsothe founding director of theLunenfeld-Tanenbaum Research Institute(LTRI) at Sinai Health, died this week nearly one year after celebrating his 100th birthday, which took place as COVID-19 forced the world to physically distance and scientists stepped up to confront the challenge of a lethal new virus.

Many former colleagues ofLou, as he was affectionately known, used the occasion tohighlight his many contributions,and U of T established acatalyst trainee awardin his name.

Lou had a transformative impact on biomedical research in Canada and around the globe, saidLeah Cowen, associate vice-president, research and former chair of molecular genetics at U of T.

He was relentless in his pursuit of research excellence, with an inspiring commitment to mentoring generations of scientists and leading scientific communities.

As a molecular biologist and pioneer in human genetics, Siminovitch made important contributions in the fields of bacterial and animal virus genetics, human genetics and cancer research, publishing more than 200 papers.

His work helped uncover the genetic bases of muscular dystrophy and cystic fibrosis, and it laid the groundwork for genetic connections to cancer.The better the science, the better the patient care, Siminovitch used to say.

Siminovitch contributed to the Nobel Prize-winning work in molecular genetics ofJacques MonodandAndre Lwoffduring his years at the Pasteur Institute in Paris. He was aninducteein the Canadian Medical Hall of Fame, and a Companion of the Order of Canada.

Daniel Druckerrecalled that when he returned from a postdoctoral position at Harvard University in the 1980s to set up a lab in Toronto as a principal investigator, a colleague suggested he speak to Siminovitch.

Lou didnt know me but he was very generous of his timeand he gave me valuable advice on grants and direction in research that continued for many years, said Drucker, a professor in the department ofmedicineat the Temerty Faculty of Medicine and a senior investigator at LTRI.

He was a strong, opinionated personality, and not everyone was thankful when, unsolicited, he told them what to do and when. But he was a huge force in building the modern molecular biology research ecosystem in Toronto, Canada and the world.

Siminovitch was renowned as a mentor and researcher, but also as a scientific builder. He played key roles in establishing and developing several top research environments in Canada, including the Ontario Cancer Institute at Princess Margaret Hospital and The Hospital for Sick Children Research Institute.

At age 65, when others might have contemplated retirement, Siminovitch was at the top of his game. Mount Sinai recruited him to build an academic research instituteand, as inaugural director, he attracted 25 of the globes most eminent scientists to the team. Thanks to his foundational efforts, LTRI is today the top-ranked biomedical research institute in Canada.

Canadian biomedical research owes a huge debt to Lou, saidJim Woodgett, a professor ofmedical biophysicsat the Temerty Faculty of Medicine and former Koffler director of research at LTRI. He instilled the importance of mentorship, of quality, and of balance and inspired us all to fulfill our potential. His impact will live on in the many scientists and leaders he inspired.

A giant of science, Siminovitch was also a well-rounded individual with wide-ranging interests in the arts and a deep commitment to family. The Elinore and Lou Siminovitch Prize in Theatre bears his name and that of his late wife, a highly respected playwright.

Even in his final years, Siminovitch could still be found regularly at LTRI often in the office of his daughter,Katherine Siminovitch, professor of medicine andimmunologyat the Temerty Faculty of Medicine and senior investigator at LTRI.

Lous leadership to the scientific and academic community changed so many careers, saidGary Newton, president and CEO of Sinai Health. His work shaped Canadian medicine in a very profound way and his impact can be seen every day in the halls and labs of Mount Sinai Hospital.

Mount Sinai Hospital will mark its 100th anniversary in 2023, and the hospitals foundation is honouring Siminovitchs achievements through aSinai 100 Chairin his name.

At U of T, theDr. Lou Siminovitch Catalyst Trainee Awardwill be awarded annually to early career faculty members to support the work of students they supervise.

Go here to see the original:
In memoriam: Louis Siminovitch, the father of genetic research in Canada - News@UofT

Animal Genetics Market | Know the Latest Innovations and Developments in the Market – BioSpace

The global animal genetics market is likely to rise at a healthy growth rate over the assessment timeframe. Augmented consumption of protein extracted from animals is prophesized to favor the growth of the global animal genetics market in the forthcoming years. In addition, increasing populations generates massive demand for animal-based protein, which further benefits the market.

The global animal genetics market has been segmented on the basis of region and product and services. The sole objective of providing such an all-inclusive report is to offer a deep insight into the market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6133

Global Animal Genetics Market: Notable Developments

The global animal genetics market has gone through a few developments in the last few years. These market developments make a manifestation of how and what is influencing the growth of the global animal genetics market. One such development is mentioned below:

Some of the key market players of the global animal genetics market are

Global Animal Genetics Market: Growth Drivers

High Demand for Animal Protein Places the Market on a High Growth Trajectory

The global animal genetics market is estimated to experience considerable growth over the review period. Such stellar growth of the market is attributed to the augmented adoption of genetic technologies and strict implementation of animal welfare regulations.

Likewise, livestock population has witnessed a substantial rise together with awareness related to the existence of animal genetic disorders. Besides, the need to cater to the unmet demands of animal protein is likely to add fillip to the global animal genetics market over the forecast timeframe.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6133&ltype=S

With an objective to produce better milk and food products, there has been an escalation in the research and development activities by several scientists. Genetic modifications are likely to emerge as another factor supporting the expansion of the global animal genetics market in forthcoming years.

The market is also prophesized to be fuelled by rapid expansion of urbanization and rise in population, which place massive demand for animal protein. Increased adoption of various advanced genetic practices like embryo transfer, artificial insemination (AI) for production of modified breed on a large scale is estimated to favor the market in the years to come.

On the other hand, the dearth of properly skilled technicians and professional with expertise in genetic services is estimate to impede the growth of the global animal genetics market in years to come. Furthermore, strict regulations related to genetic engineering of animals together with high cost of animal testing is likely to obstruct the growth of the market.

Global Animal Genetics Market: Regional Outlook

Asia Pacific, the Middle East and Africa, South America, Europe, and North America comprise the major regions of the global animal genetics market.

Considering geographies, North America is likely to play a dominant role in the global animal genetics market over the assessment timeframe. Such regional supremacy is ascribed to the presence of a large number of well-known companies of the global animal genetics market. In addition, the presence of a well-established livestock industry is likely to propel the North America animal genetics market to prominence in the near future.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6133

The global animal genetics market is segmented as:

Products and Services

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read the original post:
Animal Genetics Market | Know the Latest Innovations and Developments in the Market - BioSpace

A Genetic Variant You May Have Inherited From Neanderthals Reduces the Risk of Severe COVID-19 – SciTechDaily

New research has found that a group of genes that reduces the risk of developing severe COVID-19 by around 20% is inherited from Neanderthals. Credit: Bjorn Oberg, Karolinska Institutet

DNA variants passed on to modern humans from Neanderthals can increase as well as decrease our ability to fight SARS-CoV-2, a new PNAS study finds.

SARS-CoV-2, the virus that causes COVID-19, impacts people in different ways after infection. Some experience only mild or no symptoms at all while others become sick enough to require hospitalization and may develop respiratory failure and die.

Now, researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) in Japan and the Max Planck Institute for Evolutionary Anthropology in Germany have found that a group of genes that reduces the risk of a person becoming seriously ill with COVID-19 by around 20% is inherited from Neanderthals.

Of course, other factors such as advanced age or underlying conditions such as diabetes have a significant impact on how ill an infected individual may become, said Professor Svante Pbo, who leads the Human Evolutionary Genomics Unit at OIST. But genetic factors also play an important role and some of these have been contributed to present-day people by Neanderthals.

Last year, Professor Svante Pbo and his colleague Professor Hugo Zeberg reported in Nature that the greatest genetic risk factor so far identified, doubling the risk to develop severe COVID-19 when infected by the virus, had been inherited from Neanderthals.

Their latest research builds on a new study, published in December last year from the Genetics of Mortality in Critical Care (GenOMICC) consortium in the UK, which collected genome sequences of 2,244 people who developed severe COVID-19. This UK study pinpointed additional genetic regions on four chromosomes that impact how individuals respond to the virus.

Now, in a study published recently in Proceedings of the National Academy of Sciences (PNAS), Professor Pbo and Professor Zeberg show that one of the newly identified regions carries a variant that is almost identical to those found in three Neanderthals a ~50,000-year-old Neanderthal from Croatia, and two Neanderthals, one around 70,000 years old and the other around 120,000 years old, from Southern Siberia.

Surprisingly, this second genetic factor influences COVID-19 outcomes in the opposite direction to the first genetic factor, providing protection rather than increasing the risk to develop severe COVID-19. The variant is located on chromosome 12 and reduces the risk that an individual will require intensive care after infection by about 22%.

Its quite amazing that despite Neanderthals becoming extinct around 40,000 years ago, their immune system still influences us in both positive and negative ways today, said Professor Pbo.

To try to understand how this variant affects COVID-19 outcomes, the research team took a closer look at the genes located in this region. They found that three genes in this region, called OAS, code for enzymes that are produced upon viral infection and in turn activate other enzymes that degrade viral genomes in infected cells.

It seems that the enzymes encoded by the Neanderthal variant are more efficient, reducing the chance of severe consequences to SARS-CoV-2 infections, Professor Pbo explained.

The researchers also studied how the newly discovered Neanderthal-like genetic variants changed in frequency after ending up in modern humans some 60,000 years ago.

To do this, they used genomic information retrieved by different research groups from thousands of human skeletons of varying ages.

They found that the variant increased in frequency after the last Ice Age and then increased in frequency again during the past millennium. As a result, today it occurs in about half of people living outside Africa and in around 30% of people in Japan. In contrast, the researchers previously found that the major risk variant inherited from Neanderthals is almost absent in Japan.

The rise in the frequency of this protective Neanderthal variant suggests that it may have been beneficial also in the past, maybe during other disease outbreaks caused by RNA viruses, said Professor Pbo.

Reference: A genomic region associated with protection against severe COVID-19 is inherited from Neandertals by Hugo Zeberg and Svante Pbo, 16 February 2021, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.2026309118

The rest is here:
A Genetic Variant You May Have Inherited From Neanderthals Reduces the Risk of Severe COVID-19 - SciTechDaily

Don’t Suffer in The Cold? Turns Out There’s a Genetic Mutation For That – ScienceAlert

Most of us living on planet Earth have to make it through some amount of cold weather for at least part of the year, and new research has identified a specific genetic mutation that makes a fifth of us more resilient to cold conditions.

The genetic mutation in question stops the production of the protein -actinin-3, which is important for skeletal muscle fibre: The protein is only found in fast-twitch (or white) fibres and not in slow-twitch (or red) fibres.

Based on the new study's results, people without -actinin-3 have a higher proportion of slow-twitch fibres, and one of the consequences is that the body tends to conserve energy by building up muscle tone through contractions rather than shivering.

"This suggests that people lacking -actinin-3 are better at keeping warm and, energy-wise, at enduring a tougher climate, but there hasn't been any direct experimental evidence for this before," says physiologist Hkan Westerblad, from the Karolinska Institutet in Sweden.

"We can now show that the loss of this protein gives a greater resilience to cold and we've also found a possible mechanism for this."

The researchers recruited 42 men to sit in 14-degree Celsius (57.2-degree Fahrenheit) water while their temperatures and muscles were measured. The chilly immersion lasted 20 minutes at a time with 10-minute breaks, for up to two hours in total.

The proportion of participants who could keep their body temperature above 35.5 degrees Celsius (95.9 degrees Fahrenheit) was higher in those with the -actinin-3 mutation versus those without 69 percent of volunteers versus 30 percent.

In other words, the genetic mutation appeared to help these participants to conserve energy more efficiently and build up a greater resilience to the cold.

The team also conducted follow-up experiments in mice with the same mutation in order to check whether having this mutation could have something to do with increasing brown fat stores a well-known heat-generating tissue in mammals but that didn't turn out to be the case.

People lacking -actinin-3 might be better braced for a cold water swim or a bout of wintry weather, but it could also leave them more vulnerable to obesity and type-2 diabetes if they're inactive, the researchers say. It might also increase the risk of falling as they get older, as fast-twitch fibres handle speedy muscle movements.

"The mutation probably gave an evolutionary advantage during the migration to a colder climate, but in today's modern society this energy-saving ability might instead increase the risk of [these] diseases, which is something we now want to turn our attention to," says Westerblad.

As previous research has shown, -actinin-3 deficiency has increased across the population as humans have moved from warmer to colder climes, although questions remain about whether this mutation is present at birth and affects infant mortality.

It's also interesting to note that athletes who excel at sports involving explosiveness and strength (such as sprinting) are more likely to not have this lack of -actinin-3, while for endurance sports the stats are reversed.

As for future research, the team is keen to look at how this might all work at the molecular level, as well as how it could affect muscle disease. For now, it's an important new discovery about this genetic mutation and the allele or gene form associated with it.

"These findings provide a mechanism for the increase in [these gene variants'] frequency as modern humans migrated from Africa to the colder climates of central and northern Europe over 50,000 years ago," conclude the researchers in their published paper.

The research has been published in the American Journal of Human Genetics.

Visit link:
Don't Suffer in The Cold? Turns Out There's a Genetic Mutation For That - ScienceAlert

20% of People Have a Genetic Mutation That Provides Superior Resilience to Cold – SciTechDaily

Almost one in five people lack the protein -aktinin-3 in their muscle fiber. Researchers at Karolinska Institutet in Sweden now show that more of the skeletal muscle of these individuals comprises slow-twitch muscle fibers, which are more durable and energy-efficient and provide better tolerance to low temperatures than fast-twitch muscle fibers. The results are published in the scientific journal The American Journal of Human Genetics.

Skeletal muscle comprises fast-twitch (white) fibers that fatigue quickly and slow-twitch (red) fibers that are more resistant to fatigue. The protein -aktinin-3, which is found only in fast-twitch fibers, is absent in almost 20 percent of people almost 1.5 billion individuals due to a mutation in the gene that codes for it. In evolutionary terms, the presence of the mutated gene increased when humans migrated from Africa to the colder climates of central and northern Europe.

This suggests that people lacking -aktinin-3 are better at keeping warm and, energy-wise, at enduring a tougher climate, but there hasnt been any direct experimental evidence for this before, says Hkan Westerblad, professor of cellular muscle physiology at the Department of Physiology and Pharmacology, Karolinska Institutet. We can now show that the loss of this protein gives a greater resilience to cold and weve also found a possible mechanism for this.

For the study, 42 healthy men between the ages of 18 and 40 were asked to sit in cold water (14 C) until their body temperature had dropped to 35.5 C. During cold water immersion, researchers measured muscle electrical activity with electromyography (EMG) and took muscle biopsies to study the protein content and fiber-type composition.

The results showed that the skeletal muscle of people lacking -aktinin-3 contains a larger proportion of slow-twitch fibres. On cooling, these individuals were able to maintain their body temperature in a more energy-efficient way. Rather than activating fast-twitch fibres, which results in overt shivering, they increased the activation of slow-twitch fibers that produce heat by increasing baseline contraction (tonus).

The mutation probably gave an evolutionary advantage during the migration to a colder climate, but in todays modern society this energy-saving ability might instead increase the risk of diseases of affluence, which is something we now want to turn our attention to, says Professor Westerblad.

Another interesting question is how the lack of -aktinin-3 affects the bodys response to physical exercise.

People who lack -aktinin-3 rarely succeed in sports requiring strength and explosiveness, while a tendency towards greater capacity has been observed in these people in endurance sports, he explains.

One limitation of the study is that it is harder to study mechanisms in human studies at the same level of detail as in animal and cell experiments. The physiological mechanism presented has not been verified with experiments at, for example, the molecular level.

Reference: Loss of -actinin-3 during human evolution provides superior cold resilience and muscle heat generation by Victoria L. Wyckelsma, Tomas Venckunas, Peter J. Houweling, Maja Schlittler, Volker M Lauschke, Chrystal F. Tiong, Harrison D. Wood, Niklas Ivarsson, Henrikas Paulauskas, Nerijus Eimantas, Daniel C. Andersson, Kathryn N. North, Marius Brazaitis, Hkan Westerblad, 17 February 2021, American Journal of Human Genetics.DOI: 10.1016/j.ajhg.2021.01.013.

The study was a collaboration with research groups at the Lithuanian Sports University in Kaunas, Lithuania, and the University of Melbourne in Australia. It was supported by grants from the Swedish Research Council, the Swedish National Centre for Research in Sports, the Research Council of Lithuania, the Swedish Society for Medical Research, the Jeansson Foundations, the Swedish Heart and Lung Foundation and Australias National Health and Medical Research Council. Co-author Volker Lauschke is the founding CEO and shareholder of HepaPredict AB and has been a consultant for EnginZyme AB.

See the rest here:
20% of People Have a Genetic Mutation That Provides Superior Resilience to Cold - SciTechDaily

Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021 – GlobeNewswire

TEMPLE CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday March 4, 2021. The companys Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the companys website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 7669989. An audio replay will be available in the Investors section of the companys website or by calling (855) 859-2056 using passcode 7669989 through March 11, 2021.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633; nicole@blueshirtgroup.com

Link:
Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021 - GlobeNewswire